Methotrexate Accord Healthcare Ireland (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting dihydrofolate to tetrahydrofolate. This interruption reduces the synthesis of purines and pyrimidines, leading to impaired DNA replication and cell division, particularly affecting rapidly dividing immune and cancer cells.

The appropriate dose of methotrexate is determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Dosage regimens vary widely, and the prescriber will tailor the schedule to each individual patient.

Methotrexate is classified as pregnancy category X and is contraindicated in pregnancy because it can cause fetal malformations and loss. It is also not recommended during breastfeeding, as it may be excreted in breast milk and harm the infant. Effective contraception is required for patients of child‑bearing potential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Methotrexate belongs to the antimetabolite class and differs from alkylating agents or taxanes by targeting folate metabolism rather than DNA cross‑linking or microtubule stabilization. This mechanism offers a distinct toxicity profile and can be combined with other chemotherapies for synergistic effect, but requires careful monitoring of hematologic and hepatic parameters.

Methotrexate Accord Healthcare Ireland should be stored at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly sealed to maintain product stability.

Methotrexate can be given via intra‑arterial, intramuscular, or intrathecal injection, depending on the clinical indication and prescribing physician’s judgment. The route of administration is selected to achieve optimal drug delivery while minimizing systemic exposure and adverse effects.

Serious risks include bone‑marrow suppression leading to pancytopenia, severe hepatotoxicity or liver fibrosis, pulmonary toxicity such as interstitial pneumonitis, renal failure, and life‑threatening infections. Patients should be monitored regularly for blood counts, liver and kidney function, and any respiratory symptoms.

Methotrexate is contraindicated in pregnant women, nursing mothers, patients with severe hepatic or renal impairment, and individuals with known hypersensitivity to methotrexate or its excipients. It should also be avoided in patients receiving live vaccines or those with uncontrolled infections.